Lysogene
Lysogene is a clinical stage pioneering biotechnology company in the field of gene therapy targeting severe genetic pathologies of central nervous system in children. The company went public in 2017 on the Euronext Stock Exchange (FR0013233475 / LYS)
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
www.lysogene.com
Related News
Lysogene announces its successful IPO on Euronext Paris with nearly €22.6 m raised
Lysogene Receives Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA
Lysogene appoints Annette Clancy as Chair of the Board
Lysogène, University of Massachusetts Medical School and Auburn Unniversity announce collaboration agreement
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.